• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    9/6/23 1:31:09 PM ET
    $ACER
    $AKAN
    $APLT
    $AXLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACER alert in real time by email

    Gainers

    • NeuBase Therapeutics (NASDAQ:NBSE) stock rose 127.8% to $2.62 during Wednesday's regular session. Trading volume for this security as of 13:30 EST is 83.9 million, which is 25279.1% of its average full-day volume over the last 100 days. The company's market cap stands at $8.1 million.
    • Palisade Bio (NASDAQ:PALI) stock rose 108.96% to $1.44. As of 13:30 EST, this security is trading at a volume of 125.1 million shares, making up 53866.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.8 million.
    • Applied Therapeutics (NASDAQ:APLT) shares rose 19.84% to $1.51. As of 13:30 EST, this security is trading at a volume of 3.2 million shares, making up 1391.6% of its average full-day volume over the last 100 days. The company's market cap stands at $95.3 million.
    • Cidara Therapeutics (NASDAQ:CDTX) stock increased by 19.47% to $0.95. The current volume of 6.1 million shares is 1104.5% of Cidara Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $85.5 million.
    • Akanda (NASDAQ:AKAN) stock rose 16.54% to $0.65. Akanda's stock is trading at a volume of 1.6 million shares as of 13:30 EST. This is 628.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 million.
    • PAVmed (NASDAQ:PAVM) shares moved upwards by 15.2% to $0.47. As of 13:30 EST, PAVmed's stock is trading at a volume of 779.9K, which is 144.3% of its average full-day volume over the last 100 days. The company's market cap stands at $51.8 million.

    Losers

    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) stock fell 27.5% to $0.03 during Wednesday's regular session. Longeveron Inc. - Subscription Right's stock is trading at a volume of 128.8K shares as of 13:30 EST. This is 26.1% of its average full-day volume over the last 100 days.
    • RVL Pharmaceuticals (NASDAQ:RVLP) stock fell 22.15% to $0.11. As of 13:30 EST, RVL Pharmaceuticals's stock is trading at a volume of 4.4 million, which is 305.7% of its average full-day volume over the last 100 days. The company's market cap stands at $11.9 million.
    • Helius Medical Tech (NASDAQ:HSDT) shares declined by 16.66% to $8.33. The current volume of 491.0K shares is 139.2% of Helius Medical Tech's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $4.7 million.
    • NanoString Technologies (NASDAQ:NSTG) stock decreased by 15.83% to $2.0. NanoString Technologies's stock is trading at a volume of 1.4 million shares as of 13:30 EST. This is 104.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $94.8 million.
    • Axcella Health (NASDAQ:AXLA) shares decreased by 13.53% to $0.31. Axcella Health's stock is trading at a volume of 5.1 million shares as of 13:30 EST. This is 47.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.6 million.
    • Acer Therapeutics (NASDAQ:ACER) stock decreased by 12.25% to $0.86. The current volume of 1.3 million shares is 56.5% of Acer Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $21.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACER
    $AKAN
    $APLT
    $AXLA

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    Applied Therapeutics Inc.
    $APLT
    12/3/2025$1.00Outperform → Market Perform
    Leerink Partners
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $ACER
    $AKAN
    $APLT
    $AXLA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for OLPRUVA issued to ACER THERAPEUTICS INC

    Submission status for ACER THERAPEUTICS INC's drug OLPRUVA (ORIG-1) with active ingredient SODIUM PHENYLBUTYRATE has changed to 'Approval' on 12/22/2022. Application Category: NDA, Application Number: 214860, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/23/22 1:58:04 PM ET
    $ACER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $AKAN
    $APLT
    $AXLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial results.

    3/12/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Palisade Bio Announces Participation in Two Upcoming Investor Conferences

    Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care ConferenceDate/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation & investor meetingsWebcast link: Register here Investors registered to attend the conference who wish t

    3/2/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACER
    $AKAN
    $APLT
    $AXLA
    SEC Filings

    View All

    Amendment: SEC Form F-1/A filed by Akanda Corp.

    F-1/A - AKANDA CORP. (0001888014) (Filer)

    3/20/26 5:17:52 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Palisade Bio Inc.

    10-K - PALISADE BIO, INC. (0001357459) (Filer)

    3/20/26 4:22:38 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    2/27/26 3:57:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACER
    $AKAN
    $APLT
    $AXLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACER
    $AKAN
    $APLT
    $AXLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACER
    $AKAN
    $APLT
    $AXLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Jones Mitchell Lawrence converted options into 8,000 shares and sold $3,481 worth of shares (1,989 units at $1.75), increasing direct ownership by 83% to 13,263 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:10:12 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO, CFO Finley John David converted options into 13,333 shares and sold $6,818 worth of shares (3,896 units at $1.75), increasing direct ownership by 53% to 27,353 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:07:40 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Medical Officer Jones Mitchell Lawrence

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/11/26 5:34:45 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACER
    $AKAN
    $APLT
    $AXLA
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACER
    $AKAN
    $APLT
    $AXLA
    Financials

    Live finance-specific insights

    View All

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial results.

    3/12/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

    Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ:APLT, "Applied")), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available. "Cycle was founded with a commitment to support patients livi

    2/3/26 8:39:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $AKAN
    $APLT
    $AXLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/3/24 4:34:49 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care